Options
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Date Issued
2020
Author(s)
Beelen, Dietrich Wilhelm
Trenschel, Rudolf
Stelljes, Matthias
Groth, Christoph
Masszi, Tamás
Reményi, Péter
Wagner-Drouet, Eva-Maria
Hauptrock, Beate
Dreger, Peter
Luft, Thomas
Bethge, Wolfgang
Vogel, Wichard
Ciceri, Fabio
Peccatori, Jacopo
Stölzel, Friedrich
Junghanß, Christian
Grosse-Thie, Christina
Michallet, Mauricette
Labussiere-Wallet, Hélène
Schaefer-Eckart, Kerstin
Dressler, Sabine
Grigoleit, Goetz Ulrich
Mielke, Stephan
Scheid, Christof
Holtick, Udo
Patriarca, Francesca
Medeot, Marta
Rambaldi, Alessandro
Micò, Maria Caterina
Niederwieser, Dietger
Franke, Georg-Nikolaus
Hilgendorf, Inken
Winkelmann, Nils Rudolf
Russo, Domenico
Socié, Gérard
Peffault de Latour, Régis
Holler, Ernst
Wolff, Daniel
Glass, Bertram
Casper, Jochen
Menzel, Helge
Basara, Nadezda
Bieniaszewska, Maria
Stuhler, Gernot
Verbeek, Mareike
Grass, Sandra
Iori, Anna Paola
Finke, Juergen
Benedetti, Fabio
Pichlmeier, Uwe
Hemmelmann, Claudia
Tribanek, Michael
Klein, Anja
Mylius, Heidrun Anke
Baumgart, Joachim
Dzierzak-Mietla, Monika
Markiewicz, Miroslaw
DOI
10.1016/S2352-3026(19)30157-7
